Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICTRA adalimumab tapering versus withdrawal in rheumatoid arthritis remission
NL-OMON44460Phase 4Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Association between baseline MRI inflammation and flare in taper arm. Started Oct 2015; status: active, not recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON44460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44460.